Valproic acid increases SMN levels in spinal muscular atrophy patient cells

Citations Over TimeTop 10% of 2003 papers

Abstract

Spinal muscular atrophy (SMA) is an inherited motor neuron disease caused by mutation of the telomeric copy of the survival motor neuron gene (SMN1). Although a centromeric copy of the survival motor neuron gene (SMN2) is retained in all patients with SMA, it differs from SMN1 at a critical nucleotide such that the majority of SMN2 transcripts lack exon 7 and encode an unstable, truncated protein. Here, we show that valproic acid increases levels of exon 7-containing SMN transcript and SMN protein in type I SMA patient-derived fibroblast cell lines. Valproic acid may increase SMN levels both by activating the SMN promoter and by preventing exon 7 skipping in SMN transcripts. Valproic acid and related compounds warrant further investigation as potential treatment for SMA.

Related Papers

• → The First Orally Deliverable Small Molecule for the Treatment of Spinal Muscular Atrophy(2020)88 cited
• → Spinal Muscular Atrophy: New and Emerging Insights from Model Mice(2010)54 cited
• → SMN-Inducing Compounds For The Treatment Of Spinal Muscular Atrophy(2012)34 cited
• → Mammalian Models of Spinal Muscular Atrophy(2016)10 cited
• → Molecular genetics of spinal muscular atrophy(2023)1 cited